Merck wins FDA approval for a once-vaunted cardio drug

Damian Garde Merck picked up FDA approval for the clot-busting cardio drug vorapaxar, a treatment once billed as a potential warfarin successor before running into some alarming safety ...

Reckitt Benckiser gives up on Merck OTC deal, leaving Bayer open shot

Eric Palmer British consumer goods giant Reckitt Benckiser indicated Wednesday that bidding for the consumer healthcare unit of Merck had gotten out of hand, and so it decided to step ...

Merck bags FDA approval for its grass pollen pill

Damian Garde Merck picked up an expected FDA approval for the first of three immunotherapies in its allergy pipeline, gearing up to launch a grass pollen-fighting treatment with hopes ...

AbbVie angles for hep C spotlight as Merck shoulders to the front

Damian Garde While AbbVie is widely expected to be the second entrant to the soon-to-explode market for hepatitis C cocktail drugs after standard-bearer Gilead Sciences, promising data ...

Reckitt may top Novartis, Sanofi in $12B race for Merck consumer unit

Tracy Staton With a final bid deadline looming, Merck & Co.'s consumer health unit still has several big-name pharma suitors. But Reckitt Benckiser, the Irish consumer specialist, ...

Merck lays off its simian staff as the industry moves away from chimp research

Damian Garde Merck has joined the growing list of entities pulling the plug on chimpanzee research, folding to activist pressure and dismissing its primate subjects once and for all. FierceBiotech ...

Merck KGaA takes the long view on troubled pharma biz

Damian Garde A series of setbacks has made things tough for Merck KGaA's drug development operation, but CEO Karl-Ludwig Kley said the German company remains committed to the long-term ...

Merck recall depletes supplies of new cholesterol drug

Eric Palmer Merck & Co.'s Liptruzet has only been on the market since last May, but it will soon be unavailable. The drugmaker is asking wholesalers to return all lots they ...

Merck is cutting 150 in its Saphris sales team after selling the drug to Forest for $240M

Eric Palmer Merck early in December agreed to sell the rights to its antipsychotic drug Saphris to Forest Laboratories for $ 240 million. The move not only gave it a small cash boost, ...

Merck R&D adopts its rivals’ game plans in global overhaul

John Carroll When Merck announced back at the beginning of October that it was triggering a massive shakeup of its R&D operations after a 7-year blockbuster drought, the pharma ...

German Merck is among the companies fishing in Iran for more business

Eric Palmer With the prospect of sanctions easing, drugmakers are sizing up the opportunities in Iran, and Merck KGaA and others intend to seize them. FiercePharma News

French competition watchdog slaps Merck, Reckitt for talking down Subutex generics

Tracy Staton European antitrust watchdogs have struck again. As Reuters reports, France's competition authority has fined Merck's Schering-Plough unit €15.3 million ($ ...
Page 4 of 11« First...23456...10...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS